
Overview
Dyne Therapeutics Q2 net loss widens
Co extends cash runway into Q3 2027, supporting multiple clinical milestones
Dyne strengthens financial position with public offering and loan facility
Outlook
Dyne expects cash runway to extend into Q3 2027
Company plans U.S. Accelerated Approval submissions in 2026
Dyne anticipates DYNE-251 commercial launch in early 2027
Company pursuing approval pathways outside U.S. for DYNE-101 and DYNE-251
Result Drivers
R&D INVESTMENT - Increased R&D expenses were $99.2 million
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 EPS | Miss | -$0.97 | -$0.95 (15 Analysts) |
Q2 Net Income | Beat | -$110.86 mln | -$112.60 mln (13 Analysts) |
Q2 Operating Income | Beat | -$115.79 mln | -$136.50 mln (13 Analysts) |
Q2 Basic EPS |
| -$0.97 |
|
Q2 Operating Expenses |
| $115.79 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Dyne Therapeutics Inc is $44.50, about 77.6% above its July 25 closing price of $9.95
Press Release: ID:nGNXwYFSr